| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRUROL.2017.181 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrurol.2017.181 |
| P698 | PubMed publication ID | 29133940 |
| P2093 | author name string | Edson Antunes | |
| Fabiola Z Mónica | |||
| P2860 | cites work | Sodium nitroprusside-induced protein phosphorylation in intact rat aorta is mimicked by 8-bromo cyclic GMP | Q24629210 |
| NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 | ||
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase | Q27661554 | ||
| Insights into BAY 60-2770 Activation and S -Nitrosylation-Dependent Desensitization of Soluble Guanylyl Cyclase via Crystal Structures of Homologous Nostoc H-NOX Domain Complexes | Q27677544 | ||
| Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosum | Q28247831 | ||
| Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-aged rats: prevention by antioxidant therapy | Q28284083 | ||
| Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor | Q28299224 | ||
| Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface | Q28361083 | ||
| Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia | Q28363811 | ||
| Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme | Q28379416 | ||
| Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes | Q28575190 | ||
| Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion | Q28575510 | ||
| Effects of Testosterone Treatment in Older Men. | Q30833686 | ||
| The role of nitric oxide in bladder urothelial injury after bladder outlet obstruction | Q31104447 | ||
| NO-independent regulatory site on soluble guanylate cyclase | Q32165040 | ||
| Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample | Q33575431 | ||
| cGMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism | Q34180732 | ||
| cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action | Q34244951 | ||
| Urinary bladder contraction and relaxation: physiology and pathophysiology | Q34335220 | ||
| Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence | Q34376940 | ||
| Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment | Q34459826 | ||
| Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial | Q34631882 | ||
| Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal | Q34694719 | ||
| NO-independent, haem-dependent soluble guanylate cyclase stimulators | Q34906036 | ||
| Urethral dysfunction in diabetic rats | Q44838930 | ||
| Prevalence of and risk factors for nocturia: Analysis of a health screening program | Q44899109 | ||
| Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms | Q46215877 | ||
| Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. | Q46556756 | ||
| Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. | Q46629299 | ||
| Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra. | Q46688447 | ||
| Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice. | Q46842219 | ||
| Role of the soluble guanylyl cyclase alpha1-subunit in mice corpus cavernosum smooth muscle relaxation | Q46866011 | ||
| Temporal differences in bladder dysfunction caused by diabetes, diuresis, and treated diabetes in mice | Q46913737 | ||
| Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770. | Q46946599 | ||
| Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia | Q46974672 | ||
| Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice. | Q47334390 | ||
| Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor | Q47812722 | ||
| Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum | Q47957563 | ||
| Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure | Q48238823 | ||
| The role of estradiol in the maintenance of secondary hypogonadism in males in erectile dysfunction. | Q48418471 | ||
| Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. | Q48771717 | ||
| Bladder overactivity in mice after 1 week of outlet obstruction. Mainly afferent dysfunction? | Q48960955 | ||
| Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. | Q49115376 | ||
| Early observations of the effect of extracorporeal shockwave lithotripsy on blood pressure: a prospective randomized control clinical trial. | Q50658795 | ||
| Electrically-induced, nerve-mediated relaxation of rabbit urethra involves nitric oxide. | Q50796534 | ||
| L-arginine causes whereas L-argininosuccinic acid inhibits endothelium-dependent vascular smooth muscle relaxation. | Q50887714 | ||
| BAY 41-2272, a soluble guanylate cyclase stimulator, relaxes isolated human ureter in a standardized in vitro model. | Q51185201 | ||
| Effects of nitric oxide on human and canine prostates. | Q51608848 | ||
| European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone Therapy. | Q52710357 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| Voided volumes: normal values and relation to lower urinary tract symptoms in elderly men, a community-based study. | Q53325241 | ||
| Beneficial effect of the soluble guanylyl cyclase stimulator BAY 41-2272 on impaired penile erection in db/db-/- type II diabetic and obese mice. | Q53594364 | ||
| Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility. | Q53760527 | ||
| Increased Rho-kinase-mediated prostate contractions associated with impairment of β-adrenergic-cAMP-signaling pathway by chronic nitric oxide deficiency. | Q54280200 | ||
| Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling. | Q54375096 | ||
| Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. | Q54448773 | ||
| Implication of Rho-kinase and soluble guanylyl cyclase enzymes in prostate smooth muscle dysfunction in middle-aged rats. | Q55026414 | ||
| PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension | Q56970169 | ||
| Modulation of smooth muscle activity by nitric oxide in the human upper urinary tract | Q59265180 | ||
| Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum | Q59573052 | ||
| Long-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model | Q59573317 | ||
| Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother | Q59830662 | ||
| Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn | Q67521838 | ||
| Relaxation of sheep urethral muscle induced by electrical stimulation of nerves: involvement of nitric oxide | Q67995857 | ||
| Nitric oxide-dependent and -independent neurogenic relaxation of isolated dog urethra | Q70612476 | ||
| Inhalational nitric oxide therapy for persistent pulmonary hypertension of the newborn | Q70663501 | ||
| Nitric oxide synthase activity in the human urogenital tract | Q71678257 | ||
| Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity | Q73007219 | ||
| Soluble guanylate cyclase and cGMP-dependent protein kinase I expression in the human corpus cavernosum | Q73112611 | ||
| Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans | Q73321320 | ||
| Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum | Q73455027 | ||
| Nitric oxide in the lower urinary tract: physiology and pathological implications | Q73589928 | ||
| Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs | Q74046419 | ||
| Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I | Q74217902 | ||
| Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey | Q79831249 | ||
| Identification of residues crucially involved in soluble guanylate cyclase activation | Q79871327 | ||
| Nitric oxide produced in response to engagement of beta2 integrins on human neutrophils activates the monomeric GTPases Rap1 and Rap2 and promotes adhesion | Q80236775 | ||
| Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, ne | Q80538292 | ||
| High-fat diet associated with obesity induces impairment of mouse corpus cavernosum responses | Q85187897 | ||
| The comparison of GLUT-4 and nNOS expression in diabetic and non-diabetic patients with BPH/LUTS | Q87046641 | ||
| Blockade of renin-angiotensin system prevents micturition dysfunction in renovascular hypertensive rats | Q87992669 | ||
| Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study | Q39265763 | ||
| Nocturnal Polyuria and Hypertension in Patients with Lifestyle Related Diseases and Overactive Bladder | Q39450119 | ||
| Arterial erectile dysfunction: different severities of endothelial apoptosis between diabetic patients "responders" and "non responders" to sildenafil. | Q39477583 | ||
| Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity | Q39516918 | ||
| Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation | Q39847509 | ||
| The association between vascular risk factors and lower urinary tract symptoms in both sexes | Q40345331 | ||
| The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection | Q40372524 | ||
| Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles. | Q40397945 | ||
| A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. | Q40446987 | ||
| Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission | Q41082098 | ||
| Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway | Q41329824 | ||
| Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. | Q41513420 | ||
| Characterization and localization of nitric oxide synthase in the human prostate | Q41664812 | ||
| Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment | Q41680646 | ||
| Partial mediation by nitric oxide of the relaxation of human isolated detrusor strips in response to electrical field stimulation | Q42100841 | ||
| YC-1, a novel activator of platelet guanylate cyclase | Q42275468 | ||
| Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide | Q42361109 | ||
| Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder | Q42480137 | ||
| Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle | Q43095414 | ||
| Chronic alcoholism associated with diabetes impairs erectile function in rats. | Q43173555 | ||
| Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats | Q43248621 | ||
| Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract | Q43268622 | ||
| Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension | Q43420596 | ||
| The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. | Q43567083 | ||
| Localization of constitutive nitric oxide synthase isoforms and the nitric oxide target enzyme soluble guanylyl cyclase in the human bladder | Q43601081 | ||
| Endogenous nitric oxide-mediated relaxation and nitrinergic innervation in the rabbit prostate: the changes with aging | Q43629567 | ||
| Insulin relaxes bladder via PI3K/AKT/eNOS pathway activation in mucosa: unfolded protein response-dependent insulin resistance as a cause of obesity-associated overactive bladder. | Q43636496 | ||
| Carbon monoxide relaxes the female pig urethra as effectively as nitric oxide in the presence of YC-1. | Q43931655 | ||
| Localization and role of nitric oxide synthase and endogenous nitric oxide synthase inhibitors in the rabbit lower urinary tract | Q43961505 | ||
| Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. | Q43961522 | ||
| Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study | Q44246967 | ||
| BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. | Q44289016 | ||
| BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo | Q44322931 | ||
| Nitric oxide synthase in the external urethral sphincter of the sheep: immunohistochemical and functional study. | Q44398147 | ||
| Eccentric dosing of nitrates does not increase cardiac events in patients with healed myocardial infarction | Q44448445 | ||
| Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone | Q44594417 | ||
| Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum | Q44602629 | ||
| Pharmacological properties, functional alterations and gene expression of muscarinic receptors in young and old type 2 Goto-Kakizaki diabetic rat bladders | Q44700724 | ||
| Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels | Q35009484 | ||
| Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies | Q35044042 | ||
| Role of cyclic GMP on inhibition by nitric oxide donors of human eosinophil chemotaxis in vitro | Q35046172 | ||
| Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence | Q35112468 | ||
| Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase | Q35124292 | ||
| Functional, morphological and molecular characterization of bladder dysfunction in streptozotocin-induced diabetic mice: evidence of a role for L-type voltage-operated Ca2+ channels | Q35130556 | ||
| Nitric oxide and the lower urinary tract: current concepts, future prospects. | Q35155888 | ||
| Animal models in urological disease and sexual dysfunction | Q35545746 | ||
| Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma. | Q35586066 | ||
| Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study | Q35632649 | ||
| Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility | Q35824102 | ||
| Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro | Q35870798 | ||
| Factors involved in the relaxation of female pig urethra evoked by electrical field stimulation | Q35872779 | ||
| Nitric oxide synthase in dog urethra: a histochemical and pharmacological analysis | Q35872959 | ||
| Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study | Q35891357 | ||
| Nitric oxide synthase in pig lower urinary tract: immunohistochemistry, NADPH diaphorase histochemistry and functional effects | Q36330200 | ||
| Pharmacology of erectile dysfunction in man. | Q36380335 | ||
| Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice | Q36424922 | ||
| Multidrug resistance-associated proteins 3, 4, and 5. | Q36439713 | ||
| Proteomic modification by nitric oxide | Q36557787 | ||
| Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat | Q36674593 | ||
| Isoforms of nitric oxide synthase Characterization and purification from different cell types | Q36700509 | ||
| The sGC activator BAY 60-2770 has potent erectile activity in the rat. | Q36923923 | ||
| NO- and haem-independent soluble guanylate cyclase activators | Q37352787 | ||
| Nitric oxide and cyclic GMP signaling pathway as a focus for drug development | Q37897595 | ||
| Urological aspects of the metabolic syndrome | Q37910709 | ||
| Structure and regulation of soluble guanylate cyclase | Q37992160 | ||
| The role of phosphodiesterases in bladder pathophysiology | Q38106628 | ||
| Targeted therapies in pulmonary arterial hypertension | Q38153497 | ||
| Glucose-dependent enhancement of diabetic bladder contraction is associated with a rho kinase-regulated protein kinase C pathway | Q38358487 | ||
| Novel methods for mapping the cavernous nerves during radical prostatectomy | Q38563494 | ||
| Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome | Q38692706 | ||
| Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia | Q38710302 | ||
| Path of translational discovery of urological complications of obesity and diabetes | Q38774808 | ||
| Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin | Q38807815 | ||
| Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction | Q38902584 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 42-54 | |
| P577 | publication date | 2017-11-14 | |
| P1433 | published in | Nature Reviews Urology | Q2079265 |
| P1476 | title | Stimulators and activators of soluble guanylate cyclase for urogenital disorders | |
| P478 | volume | 15 |
| Q88393495 | PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery |
| Q64285454 | Radial Extracorporeal Shock Wave Therapy as a Novel Agent for Benign Prostatic Hyperplasia Refractory to Current Medical Therapy |
| Q91341634 | TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells |
Search more.